Suppr超能文献

为每个人选择和使用适当的流感疫苗。

Selecting and Using the Appropriate Influenza Vaccine for Each Individual.

机构信息

International Institute for Zoonosis Control, Hokkaido University, Kita-20 Nishi-10, Kita-ku, Sapporo 001-0020, Japan.

International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.

出版信息

Viruses. 2021 May 24;13(6):971. doi: 10.3390/v13060971.

Abstract

Despite seasonal influenza vaccines having been routinely used for many decades, influenza A virus continues to pose a global threat to humans, causing high morbidity and mortality each year. The effectiveness of the vaccine is largely dependent on how well matched the vaccine strains are with the circulating influenza virus strains. Furthermore, low vaccine efficacy in naïve populations such as young children, or in the elderly, who possess weakened immune systems, indicates that influenza vaccines need to be more personalized to provide broader community protection. Advances in both vaccine technologies and our understanding of influenza virus infection and immunity have led to the design of a variety of alternate vaccine strategies to extend population protection against influenza, some of which are now in use. In this review, we summarize the progress in the field of influenza vaccines, including the advantages and disadvantages of different strategies, and discuss future prospects. We also highlight some of the challenges to be faced in the ongoing effort to control influenza through vaccination.

摘要

尽管季节性流感疫苗已被常规使用了几十年,但甲型流感病毒仍持续对人类构成全球性威胁,每年导致大量发病和死亡。疫苗的有效性在很大程度上取决于疫苗株与流行的流感病毒株的匹配程度。此外,在儿童等初免人群或免疫系统较弱的老年人等人群中,疫苗效力较低,表明流感疫苗需要更加个性化,以提供更广泛的社区保护。疫苗技术的进步以及我们对流感病毒感染和免疫的理解,促使设计了各种替代疫苗策略,以扩大人群对流感的保护,其中一些策略现已投入使用。在这篇综述中,我们总结了流感疫苗领域的进展,包括不同策略的优缺点,并讨论了未来的前景。我们还强调了在通过疫苗接种控制流感的持续努力中将要面临的一些挑战。

相似文献

1
Selecting and Using the Appropriate Influenza Vaccine for Each Individual.
Viruses. 2021 May 24;13(6):971. doi: 10.3390/v13060971.
2
Advances in the development of universal influenza vaccines.
Influenza Other Respir Viruses. 2013 Sep;7(5):750-8. doi: 10.1111/irv.12013. Epub 2012 Sep 24.
3
Vaccines for seasonal and pandemic influenza.
J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8. doi: 10.1086/507544.
5
Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.
6
Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.
Influenza Other Respir Viruses. 2012 Mar;6(2):142-52, e1-5. doi: 10.1111/j.1750-2659.2011.00277.x. Epub 2011 Aug 8.
7
Current challenges: from the path of "original antigenic sin" towards the development of universal flu vaccines.
Int Rev Immunol. 2020;39(1):21-36. doi: 10.1080/08830185.2019.1685990. Epub 2019 Nov 9.
9
Towards a universal influenza vaccine: different approaches for one goal.
Virol J. 2018 Jan 19;15(1):17. doi: 10.1186/s12985-017-0918-y.

引用本文的文献

1
Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium.
Front Immunol. 2025 May 23;16:1568778. doi: 10.3389/fimmu.2025.1568778. eCollection 2025.
2
Neurological Manifestations of Influenza Vaccination: A Narrative Review.
Cureus. 2025 Apr 29;17(4):e83228. doi: 10.7759/cureus.83228. eCollection 2025 Apr.
3
Progress Update on STING Agonists as Vaccine Adjuvants.
Vaccines (Basel). 2025 Mar 31;13(4):371. doi: 10.3390/vaccines13040371.
6
Revolutionizing Nanovaccines: A New Era of Immunization.
Vaccines (Basel). 2025 Jan 27;13(2):126. doi: 10.3390/vaccines13020126.
7
The Impact of Vaccinations Against Respiratory Infections on the Prognosis in Heart Failure Patients.
Vaccines (Basel). 2024 Nov 26;12(12):1321. doi: 10.3390/vaccines12121321.
8
Mannose and Lactobionic Acid in Nasal Vaccination: Enhancing Antigen Delivery via C-Type Lectin Receptors.
Pharmaceutics. 2024 Oct 8;16(10):1308. doi: 10.3390/pharmaceutics16101308.

本文引用的文献

1
Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine.
Vaccines (Basel). 2021 Mar 13;9(3):257. doi: 10.3390/vaccines9030257.
2
COVID-19 vaccines: modes of immune activation and future challenges.
Nat Rev Immunol. 2021 Apr;21(4):195-197. doi: 10.1038/s41577-021-00526-x.
3
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
4
Global production capacity of seasonal and pandemic influenza vaccines in 2019.
Vaccine. 2021 Jan 15;39(3):512-520. doi: 10.1016/j.vaccine.2020.12.018. Epub 2020 Dec 16.
5
Oxford-AstraZeneca COVID-19 vaccine efficacy.
Lancet. 2021 Jan 9;397(10269):72-74. doi: 10.1016/S0140-6736(20)32623-4. Epub 2020 Dec 8.
9
Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults.
Clin Transl Immunology. 2020 Feb 3;9(2):e1107. doi: 10.1002/cti2.1107. eCollection 2020.
10
Effects of Influenza Vaccination in the United States During the 2018-2019 Influenza Season.
Clin Infect Dis. 2020 Nov 5;71(8):e368-e376. doi: 10.1093/cid/ciz1244.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验